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Abstract
Background: Recent analysis of trends of non-invasive infections with methicillin resistant Staphylococcus aureus
(MRSA), of trends of MRSA infections in outpatient settings and of co-resistance profiles of MRSA isolates are scarce
or lacking in Germany.
Methods: We analysed data from the Antimicrobial Resistance Surveillance Network (ARS). We included in the
analysis the first isolate of S. aureus per patient and year, which had a valid test result for oxacillin resistance and
which was not a screening sample. We limited the analysis to isolates from facilities, which contributed to ARS for
all six years between 2010 and 2015. We compared the proportion of methicillin resistance among S. aureus isolates
by calendar year using Chi-square and Fisher’s exact test. We corrected for multiple testing using the Bonferroni
correction. We stratified the analysis by sample type including various non-invasive sample types and by type of
care (e.g. hospital versus outpatient clinic). We also analysed the non-susceptibility of MRSA to selected antibiotics.
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Results: The analysis included 148,561 S. aureus isolates. The distribution of these isolates by sex, age, region, sample
type, clinical speciality and type of care remained relatively stable over the six years analysed. The proportion of
MRSA among S. aureus isolates decreased continuously from 16% in 2010 to 10% in 2015. This decrease was seen for
all types of care and for the majority of sample types, including the outpatient clinic (12 to 8%), as well as blood culture
(19 to 9%), urine samples (25 to 15%), swabs (14 to 9%), respiratory samples (22 to 11%) and lesions (15 to 10%). The
non-susceptibility of MRSA isolates to tobramycin (47 to 32%), ciprofloxacin (95 to 89%), moxifloxacin (94 to 84%),
clindamycin (80 to 71%) and erythromycin (81 to 72%) declined markedly, but it increased for tetracyclines
(6 to 9%) and gentamicin (3 to 6%). Non-susceptibility of MRSA to linezolid, teicoplanin, tigecycline and
vancomycin remained rare.
Conclusion: This analysis indicates that the incidence of MRSA infections declined in a variety of settings in
Germany between 2010 and 2015 and that the co-resistance profiles of MRSA isolates changed markedly.
Keywords: Antimicrobial resistance, Methicillin-resistant Staphylococcus aureus (MRSA), Surveillance, Livestock-
associated MRSA, Germany
Background
The incidence of infections with methicillin resistant
Staphylococcus aureus (MRSA) is thought to be on the
decline in Germany. This is corroborated by data from
the national mandatory reporting system [1], from a hos-
pital surveillance system [2], from surveys [3] and from
analysis of data submitted to the European Antimicro-
bial Resistance Surveillance Network [4]. However, these
analyses rely on invasive samples or on samples from
hospitals only. Little is known about trends in the inci-
dence of non-invasive MRSA infections and about that
of MRSA infections in outpatient settings [5, 6].
The MRSA epidemic in Germany and Europe is
thought to be mainly health-care associated based on
the age distribution of cases [1] and molecular analysis
of the isolates [7]. However, there are regions with a high
density of swine farming, where livestock-associated
(LA) MRSA makes up a considerable proportion of
MRSA infections seen in hospitals. For example, one
study found 8% of all MRSA blood cultures to be associ-
ated with LA-MRSA [8]. Community-associated (CA)
MRSA is regularly found throughout Germany, even
though it remains relatively rare [9]. Trends for LA- and
CA-MRSA are not well reflected by the above men-
tioned surveillance systems, since this would require a
more thorough data collection, ideally including the mo-
lecular characterization of isolates.
The Antimicrobial Resistance Surveillance Network
(ARS) collects routine data on antibiotic resistance test-
ing from voluntarily participating laboratories [10]. In
contrast to other surveillance systems, ARS includes
data on antibiotic susceptibility testing of S. aureus iso-
lates from a number of sample types and settings includ-
ing non-invasive samples and outpatient settings. It also
includes data on co-resistance to other antibiotics for a
large number of MRSA isolates. To complement recent
analysis of declining MRSA infections in invasive
samples and in hospitals [1–4] and to extend previous
analysis from ARS [5, 11], we investigated whether de-
clining trends of MRSA may be seen for all clinical set-
tings, including outpatient settings, and for all sample
types, including non-invasive samples. We further inves-




Among all data submitted to ARS, we selected facilities
who submitted data for the entire study period from
2010 to 2015. We excluded screening samples (i.e. those
marked as screening samples, those collected from
swabs from the nose/throat and anal swabs) as well as
those from unspecified sample types. We selected the
first isolate of S. aureus per patient and year that had a
valid test result for oxacillin (or to a comparable anti-
biotic, such as cefoxitin). We compared the proportion
of S. aureus isolates that are resistant to oxacillin by year
and stratified the analysis by type of care or by sample
type. Among oxacillin resistant isolates we compared the
proportion that were non-susceptible to other selected
antibiotics by year.
Statistical analysis
We grouped sample types into 7 groups: In addition to
blood culture and urine, we included swabs from lesions
and abscesses in one group (“lesions”). We grouped
together swabs from eyes, ears, tonsils/throat, tongue,
urogenital tract, those collected during surgery, as well
as other and non-specified swabs (“swabs”). We also
grouped together biopsies from tissues, liquor, abscesses,
ascites, joints, pleural cavity, other and non-specified
punctures (“biopsies”). We grouped together bronchial
lavage, bronchial secretions, sputum, tracheal secretion
and other respiratory samples (“respiratory sample”).
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The remaining samples were dialysate, ejaculate, skin,
hairs, nails, catheters, faeces and unspecified samples
(“other samples”). For the analysis of co-resistance, we
used non-susceptibility as the outcome, grouping
together resistant and intermediate test results. Due to
cross-resistance between tetracycline and doxycycline,
we grouped these two antibiotics together as the group
of tetracyclines. In the analysis stratified by federal
Table 1 Number and characteristics of S. aureus isolates included in the analysis, ARS, Germany 2010-2015
2010 [n (%)] 2011 [n (%)] 2012 [n (%)] 2013 [n (%)] 2014 [n (%)] 2015 [n (%)] p-value
N 24 667 25 125 25 995 25 544 25 028 22 202
Age [years] <0.001
0–9 2 170 (9) 2 163 (9) 2 210 (9) 1 969 (8) 1 673 (7) 1 524 (7)
10–19 1 321 (5) 1 335 (5) 1 461 (6) 1 319 (5) 1 199 (5) 1 105 (5)
20–29 1 440 (6) 1 551 (6) 1 522 (6) 1 531 (6) 1 501 (6) 1 333 (6)
30–39 1 349 (5) 1 394 (6) 1 378 (5) 1 369 (5) 1 269 (5) 1 203 (5)
40–49 2 049 (8) 2 175 (9) 2 144 (8) 2 043 (8) 1 864 (7) 1 687 (8)
50–59 2 721 (11) 2 736 (11) 2 945 (11) 2 892 (11) 2 878 (11) 2 588 (12)
60–69 3 446 (14) 3 497 (14) 3 493 (13) 3 611 (14) 3 569 (14) 3 150 (14)
70–79 5 439 (22) 5 491 (22) 5 714 (22) 5 771 (23) 5 657 (23) 4 830 (22)
80+ 4 732 (19) 4 783 (19) 5 128 (20) 5 039 (20) 5 418 (22) 4 782 (22)
Sex <0.001
Women 8 764 (36) 9 159 (36) 9 728 (37) 10 640 (42) 10 144 (41) 9 204 (41)
Men 10 151 (41) 10 412 (41) 11 215 (43) 11 995 (47) 11 646 (47) 10 242 (46)
Not specified 5 752 (23) 5 554 (22) 5 052 (19) 2 909 (11) 3 238 (13) 2 756 (12)
Federal state <0.001
Baden-Württemberg 4 634 (19) 4 844 (19) 4 709 (18) 4 882 (19) 2 839 (11) 2 886 (13)
Bavaria 609 (2) 565 (2) 635 (2) 688 (3) 714 (3) 784 (4)
Berlin 1 678 (7) 1 885 (8) 1 889 (7) 2 029 (8) 2 108 (8) 2 218 (10)
Hesse 848 (3) 832 (3) 1 045 (4) 1 125 (4) 1 203 (5) 1 283 (6)
North Rhine-Westphalia 11 778 (48) 11 838 (48) 12 465 (48) 12 758 (50) 13 809 (56) 10 652 (49)
Rhineland Palatinate 2 387 (10) 2 322 (9) 2 351 (9) 2 301 (9) 2 512 (10) 2 397 (11)
Schleswig-Holstein 2 511 (10) 2 598 (10) 2 659 (10) 1 524 (6) 1 622 (7) 1 728 (8)
Sample type <0.001
Swabs 9 352 (38) 9 383 (37) 9 720 (37) 8 819 (35) 8 669 (35) 8 077 (36)
Blood cultures 1 109 (4) 1 172 (5) 1 263 (5) 1 262 (5) 1 250 (5) 1 093 (5)
Biopsies 469 (2) 505 (2) 528 (2) 560 (2) 459 (2) 410 (2)
Respiratory samples 2 537 (10) 2 523 (10) 2 624 (10) 2 687 (11) 2 508 (10) 2 345 (11)
Urine 2 494 (10) 2 508 (10) 2 569 (10) 2 456 (10) 2 508 (10) 1 973 (9)
Lesions 8 118 (33) 8 427 (34) 8 701 (33) 9 098 (36) 9 109 (36) 7 795 (35)
Other 588 (2) 607 (2) 590 (2) 662 (3) 525 (2) 509 (2)
Type of care 0.016
Outpatient care 10 846 (44) 11 537 (46) 11 588 (45) 11 506 (46) 10 811 (44) 10 209 (46)
ICU 1 798 (7) 1 857 (7) 2 002 (8) 1 875 (7) 1 716 (7) 1 620 (7)
Normal hospital ward 11 920 (49) 11 600 (46) 12 104 (47) 11 793 (47) 12 001 (49) 10 223 (46)
Clinical specialty <0.001
Surgery and related 5 208 (21) 5 040 (20) 5 226 (20) 5 047 (20) 4 832 (19) 3 843 (17)
Internal/conservative 12 160 (49) 12 339 (49) 12 652 (49) 12 620 (49) 12 355 (49) 10 949 (49)
Other 7 299 (30) 7 746 (31) 8 117 (31) 7 877 (31) 7 841 (31) 7 410 (33)
ICU = intensive care unit. The numbers may not tally to the total due to missing data or due to a low frequency of entries, which do not fit the categories shown
(i.e. for type of care and for federal state)
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states, we excluded samples from several states with data
for only few patients.
For univariate analysis we used chi-square tests unless
the expected cell count was below 5, in which case we
used Fisher’s exact test. We corrected for multiple test-
ing using Bonferroni correction (i.e. dividing the p-value
of 0.05 by the number of conducted tests [i.e. 27 for
temporal differences in the frequency of oxacillin resist-
ance; 6 for factors associated with non-susceptibility to
tetracyclines]).
Results
Characteristics of included isolates
The analysis included 148,561 isolates from 6 laborator-
ies representing 1,855 different outpatient clinics and
105 hospitals. Even though statistically significant,
changes over the years were generally small for the dis-
tribution of the samples by category of age, sex, federal
state of the sending facility, sample type, type of care or
clinical speciality (Table 1).
Oxacillin resistance
The overall frequency of oxacillin resistance decreased
continuously from 16% (n = 4,058) in 2010, to 15% (n
= 3,853) in 2011, 14% (n = 3,675) in 2012, 12% (n =
3,129) in 2013, 12% (n = 2,974) in 2014 to 10% (n =
2,223) in 2015 (p < =0.001).
There were significant declines in the proportion of
MRSA among all S. aureus isolates for all types of
care (Fig. 1, upper panel). As expected, the proportion
of MRSA was generally lower in the outpatient
Fig. 1 MRSA among S. aureus isolates by type of care or sample type, ARS, Germany, 2010–2015. Legend: The asterisk marks significant
changes (p < 0.0019)
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setting than in hospitals. However, the relative decline
was markedly lower in the outpatient setting than in
the hospital setting (12 to 8% between 2010 and 2015
versus 26 to 11% in ICU and 19 to 12% in non-ICU
hospital wards), closing the gap between these two
types of care.
There was a strong decline in the proportion of
MRSA among S. aureus isolates for all sample types
except for biopsies and other samples, for which the
p-value did not reach statistical significance after ad-
justment for multiple testing (i.e. p < 0.0019) (Fig. 1,
lower panel).
Non-susceptibility of MRSA to other antibiotics
Figure 2 depicts the non-susceptibility of MRSA iso-
lates to other selected antibiotics per calendar year.
At least three different patterns can be identified:
Firstly, antibiotics with high (>30%) but decreasing
levels of non-susceptibility (i.e. tobramycin, ciproflox-
acin, moxifloxacin, clindamycin, erythromycin); sec-
ondly, antibiotics with low (≤5%) and decreasing or
stable levels of non-susceptibility (i.e. teicoplanin,
vancomycin, daptomycin, fosfomycin, fusidic acid,
linezolid, mupirocin, rifampicin, cotrimoxazole and
tigecyline); thirdly, two antibiotics or groups of antibi-
otics with relatively low levels (<10%) but increasing
levels of non-susceptibility (i.e. gentamicin and tetra-
cyclines). The absolute numbers of isolates with non-
susceptibility to gentamicin (2010 to 2015: n = 135,
145, 164, 104, 114 and 130) or to tetracyclines (2010
to 2015: n = 225, 293, 262, 233, 282 and 203)
remained relatively stable over the years, due to the
decline in the overall number of MRSA isolates.
Since non-susceptibility to tetracyclines has been
found to be associated with LA-MRSA in several studies
[12–18], we analysed the associated factors. We found
non-susceptibility to tetracyclines to be associated with
young age (Table 2). While there was no difference be-
tween the two sexes (p = 0.13), non-susceptibility was
higher if for technical reasons the sex had not been spe-
cified. There were also significant differences between
German federal states, however with no clear pattern.
Non-susceptibility was relatively high among isolates
from swabs, biopsies, lesions and other samples, but
lower in isolates from blood culture. As expected it was
higher in samples from outpatient settings than from
hospitals (p = 0.004 for outpatient versus both hospital
settings). Non-susceptibility to tetracyclines was more
frequent among isolates from surgery than in those from
other clinical specialities.
Discussion
The proportion of MRSA among S. aureus isolates
from non-invasive samples and from those in the out-
patient setting decreased significantly between 2010
and 2015. Similarly, non-susceptibility of MRSA iso-
lates to several other antibiotics decreased between
2010 and 2015, while that to gentamicin and to tetra-
cyclines increased. Non-susceptibility to last line anti-
biotics, including tigecycline, linezolid, vancomycin
and teicoplanin, fortunately remained rare.
Our data are also consistent with previous analyses
that have indicated declines in MRSA in the hospital
Fig. 2 Non-susceptibility of MRSA isolates to selected antibiotics, ARS, Germany, 2010–2015. Legend: The table shows the number of tested
isolates. The asterisk marks significant changes (p < 0.0019)
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setting and for invasive infections [1–3], with the previ-
ous analysis of ARS data from outpatient setting [5] and
indirectly also with data from the national reference
laboratory that suggest low levels of LA- and CA-MRSA
in Germany [6, 9]. Therefore, they indicate a general
decline in MRSA-infection in Germany in all settings
and for all sample types.
A decline in MRSA infections in Germany may have
various reasons as discussed previously [1]. It is likely
that control mechanisms implemented in Germany con-
tribute to this success. However, additional factors, such
as normally occurring changes in the circulating strains
cannot be excluded [19].
Of note is the relative increase in the non-susceptibility
of MRSA isolates to tetracyclines. Non-susceptibility to
tetracyclines had been found to be associated with
LA-MRSA [13–18]. We found it to be associated with
–among other factors - young age and samples from
outpatient settings, which would be consistent with
LA-MRSA. Since, however, non-susceptibility to tetra-
cyclines also occurs independently of LA-MRSA [12],
we cannot with certainty attribute trends in non-
susceptibility to tetracyclines to an increase in LA-
MRSA. An increase in the proportion of LA-MRSA
among all MRSA isolates would however be consist-
ent with two previous studies that showed an increase
of LA-MRSA between 2004/2005 and 2010/2011 [20]
as well as stable levels of LA-MRSA in recent years
[12] (while other forms of MRSA have declined). The
relevance of LA-MRSA in Germany therefore war-
rants further investigations.
The proportion of MRSA among S. aureus isolates is
an imperfect indicator for the incidence of MRSA infec-
tions, because it may be influenced by the frequency of
diagnostic sampling [21], the time of sample collection,
changes in treatment practice and because it does not
include a defined population as denominator. As with all
routine data from voluntary sources, an additional limi-
tation of this analysis is the possibility of a changing
study base and a potential non-representativeness of the
data for all of Germany. Since, however, the baseline
characteristics (Table 1) remained relatively stable over
the time period included in the study and since the re-
sults for the blood cultures showed consistent trends
with data from other sources [1, 2], we believe our
results to be indicative for trends in the incidence of
MRSA infections in Germany.
Conclusion
The presented data from ARS corroborate a general de-
cline of MRSA infections in Germany including in the
outpatient setting and in non-invasive samples. The co-
resistance profiles changed markedly and should be fur-
ther analysed using genotyping studies.
Table 2 Non-susceptibility of MRSA isolates to tetracyclines,









N 19 721 1 498 (8)
Age [years] <0.001
0–9 414 79 (19)
10–19 216 45 (21)
20–29 367 64 (17)
30–39 436 75 (17)
40–49 936 107 (11)
50–59 1 883 180 (10)
60–69 3 219 252 (8)
70–79 6 093 357 (6)
80+ 6 157 339 (6)
Sex <0.001
Women 6 449 428 (7)
Men 8 736 635 (7)
Unspecified 4 536 435 (10)
Federal state <0.001
Baden-Württemberg 2 544 134 (5)
Bavaria 336 47 (14)
Berlin 1 248 84 (7)
Hesse 664 40 (6)
North Rhine-
Westphalia
11 445 942 (8)
Rhineland Palatinate 1 790 86 (5)




6 059 498 (8)
Blood culture 926 43 (5)
Biopsies 302 32 (11)
Respiratory sample 2 538 183 (7)
Urine 3 006 166 (6)
Lesion 6 455 541 (8)
Other 435 35 (8)
Type of care 0.016
Outpatient care 6 668 553 (8)
Intensive care unit 2 048 142 (7)
Normal hospital ward 10 780 776 (7)
Clinical specialty 0.001
Surgery 3 943 348 (9)
Internal/conservative 10 645 748 (7)
Other 5 133 402 (8)
The numbers may not tally to the total due to missing data or due to a low
frequency of entries, which do not fit the categories shown (i.e. for type of
care and for federal state)
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